RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC
Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Center, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
630 Madison Ave.
Manalapan, NJ 07726
Contributors and Partners
Cancer Nursing Today
Urban Health Today
Blood Cancers Today
© 2023 Mashup Media, LLC. All rights reserved.